LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Single Mutation Causes Two Separate Neurodegenerative Diseases

By LabMedica International staff writers
Posted on 04 Jan 2017
Print article
Image: Mutations associated with Alzheimer\'s disease alter the surface structure of the TREM2 protein, while mutations linked to Nasu-Hakola disease disrupt the protein\'s interior. Such alterations may impair TREM2\'s normal role in removing cellular waste via phagocytosis (Photo courtesy of Daniel L. Kober, Washington University School of Medicine).
Image: Mutations associated with Alzheimer\'s disease alter the surface structure of the TREM2 protein, while mutations linked to Nasu-Hakola disease disrupt the protein\'s interior. Such alterations may impair TREM2\'s normal role in removing cellular waste via phagocytosis (Photo courtesy of Daniel L. Kober, Washington University School of Medicine).
Resolution of the X-ray crystallography structure of variants of TREM2 (Triggering receptor expressed on myeloid cells 2) protein revealed that mutations responsible for Nasu-Hakola disease were buried deep within the core of the folded protein, while mutations associated with Alzheimer’s disease resided on the surface of the protein.

Individuals with rare mutations in the gene that encodes the TREM2 protein have a substantial risk of developing Alzheimer’s disease in their mid-60s. A different set of mutations in the same gene can cause a more severe degenerative brain disease known as Nasu-Hakola disease in much younger people. The mutations causing Alzheimer’s and Nasu-Hakola disease result in the production of mutant TREM2 proteins that differ from the normal protein by only a single amino acid. It is not clear how different mutations affecting the same protein can give rise to two distinct neurodegenerative diseases.

To address this question, investigators at Washington University School of Medicine (St. Louis, MO, USA) used X-ray crystallography to construct three-dimensional models of the proteins at a resolution of 3.1 Angstroms. These models revealed that mutations found in Nasu-Hakola disease were buried within the protein whereas Alzheimer’s disease risk variants were found on the surface, suggesting that these mutations had distinct effects on TREM2 function.

Biophysical and cellular methods indicated that Nasu-Hakola mutations impacted protein stability and decreased folded TREM2 surface expression, whereas Alzheimer’s risk variants impacted binding to the TREM2 glycosaminoglycans ligands. Additionally, the Alzheimer’s risk variants appeared to epitope map a functional surface on TREM2 that was unique within the larger TREM family.

“We do not know exactly what dysfunctional TREM2 does to contribute to neurodegeneration, but we know inflammation is the common thread in all these conditions,” said senior author Dr. Thomas J. Brett, assistant professor of medicine at Washington University School of Medicine. “Our study looked at these mutations in TREM2 and asked what they do to the structure of the protein itself, and how that might impact its function. If we can understand that, we can begin to look for ways to correct it.”

“Exactly what TREM2 does is still an open question,” said Dr. Brett. “We know mice without TREM2 have defects in microglia, which are important in maintaining healthy brain biology. Now that we have these structures, we can study how TREM2 works, or does not work, in these neurodegenerative diseases. TREM2 also has been implicated in other inflammatory conditions, including chronic obstructive pulmonary disease and stroke, making the structure of TREM2 important for understanding chronic and degenerative diseases throughout the body.”

The study was published in the December 20, 2016, online edition of the journal eLife.

Related Links:
Washington University School of Medicine

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more